公司概覽
業務類別 Biotechnology
業務概覽 Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
公司地址 Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
電話號碼 +31 107038441
傳真號碼 --
公司網頁 https://www.argenx.com
員工數量 3522
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Tim Van Hauwermeiren, M. Sc. Executive Director and Chief Executive Officer 美元 757.68K 20/03/2025
Mr. Arjen Lemmen Vice President, Corporate Development and Strategy -- 20/03/2025
Ms. Andria Wilk Global Head, Quality -- 20/03/2025
Mr. Karl Gubitz Chief Financial Officer 美元 553.00K 20/03/2025
Ms. Malini Moorthy General Counsel -- 20/03/2025
Dr. Luc Truyen, M.D.,PhD Chief Medical Officer -- 20/03/2025
Dr. Peter Ulrichts Chief Scientific Officer -- 20/03/2025
Ms. Karen Massey Chief Operating Officer 美元 655.66K 20/03/2025
 
董事會成員
董事會 職務 更新日期
Mr. James M. Daly Independent Director 20/03/2025
Mr. Steven E. Krognes, M.B.A. Independent Director 20/03/2025
Mr. Tim Van Hauwermeiren, M. Sc. Executive Director and Chief Executive Officer 20/03/2025
Mr. Peter K.M. Verhaeghe Non-Executive Chairman of the Board 20/03/2025
Dr. J. Donald deBethizy, PhD Independent Director 20/03/2025
Dr. Pamela M. Klein, M.D. Independent Director 20/03/2025
Mr. Anthony A. Rosenberg Independent Director 20/03/2025
Dr. Brian L. Kotzin, M.D. Independent Director 20/03/2025
Ms. Camilla Sylvest Independent Director 20/03/2025
Dr. Ana Cespedes, PhD Independent Director 20/03/2025
 
所屬ETF (更新日期: 07/11/2026 02:41)
代號 名稱 佔比% ▼ 持有日期
TBXUDirexion Daily Biotech Top 5 Bull 2X ETF0.001%31/10/2026
IBRNiShares Neuroscience and Healthcare ETF0.0005%30/10/2026
VUSGVanguard Wellington U.S. Gr Actv ETF0.0005%30/09/2026
BMEDiShares Health Innovation Active ETF0.0004%30/10/2026
ESIMEventide International ETF0.0004%30/10/2026
GDOCGoldman Sachs Future Health Care Eq ETF0.0004%30/10/2026
IFLRInnovator International Dev Mgd Flr ETF0.0004%30/10/2026
AVNCAvantis All International Cor Eq ETF0.0003%30/10/2026
AAUBAlpha Architect US Equity 4 ETF0.0003%30/10/2026
JSTCAdasina Social Justice All Cp Glbl ETF0.0002%30/10/2026
SROICalamos Antetokounmpo Global Sus Eqs ETF0.0002%31/08/2026
PJINPGIM Jennison International Core Eq ETF0.0001%30/10/2026
FHILFederated Hermes International Ldrs ETF0.0001%30/10/2026
TNXTT. Rowe Price Innovation Leaders ETF0.0001%31/10/2026
IBFRInnovator International Dev Mgd 10BfrETF0.0001%30/10/2026
WDNAWisdomTree BioRevolution ETF0.0001%30/10/2026
DXIVDimensional International Vector Eq ETF0.00002%30/10/2026
AVUCAvantis U.S. Core Equity ET0.00001%30/10/2026
OTAXOptimal Tax Managed Equity ETF0.00001%30/10/2026
ACMGAmerican Century Mid Cap Gr Insgts ETF<0.000001%31/03/2026
  1    2    3   4    5  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.